Compare Immunovant Inc. Common Stock (IMVT) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Kaltura Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Kaltura Inc trades at $1.32 (market cap $202.89M). The key difference: Immunovant Inc. Common Stock is far larger — about 32.6× Kaltura Inc's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Kaltura Inc for 21 Days on average.
| IMVT | KLTR | |
|---|---|---|
Market Cap | $6.62B | $202.89M |
Volume | 1,131,364 | 214,400 |
Sector | Health | Technology |
52-Week High | $44.96 | $1.89 |
52-Week Low | $17.03 | $1.08 |
Typical Hold Time | 0 Days | 21 Days |
Enterprise Value | $5.72B | $215.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kaltura (KLTR) trades at $1.33, up 3.91% with recent earnings beats but negative profitability. Technical indicators show bearish momentum while fundamentals reveal improving margins despite net losses. The company is gaining industry recognition for AI-powered video platforms and secured major partnerships, though cash flow remains negative.
Investment outlook balances AI innovation potential against persistent financial challenges. While analyst sentiment leans positive with 44% buy ratings, high valuation multiples and negative ROE present significant risks. The stock offers speculative appeal for investors betting on AI-driven turnaround despite current unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
